Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8436185 | GLAXOSMITHKLINE | Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide |
Apr, 2029
(6 years from now) | |
US8071623 | GLAXOSMITHKLINE | Amide substituted indazoles as poly(ADP-ribose)polymerase(PARP) inhibitors |
Mar, 2031
(8 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8071579 | GLAXOSMITHKLINE | DNA damage repair inhibitors for the treatment of cancer |
Aug, 2027
(4 years from now) | |
US8143241 | GLAXOSMITHKLINE | DNA damage repair inhibitors for treatment of cancer |
Aug, 2027
(4 years from now) | |
US8859562 | GLAXOSMITHKLINE | Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer |
Aug, 2031
(8 years from now) | |
US11091459 | GLAXOSMITHKLINE | Niraparib compositions |
Mar, 2038
(15 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Apr 29, 2027 |
New Chemical Entity Exclusivity (NCE) | Mar 27, 2022 |
New Indication (I) | Apr 29, 2023 |
NCE-1 date: March, 2021
Market Authorisation Date: 27 March, 2017
Treatment: A method of treatment of advanced ovarian, fallopian tube, or primary peritoneal cancer associated with homologous recombination deficiency (hrd) positive status
Dosage: CAPSULE;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic